

| | | | |
|-----------------------------------|--|---|---|
| SERVICE AREA | Georgia | | |
| LINES OF BUSINESS (LOB) | <p style="text-align: center;">Effective February 1, 2021 Peach State Health Plan (Medicaid) Ambetter from Peach State Health Plan (Exchange) Effective January 1, 2025 ICHRA Membership</p> <p style="text-align: center;">Members of all ages</p> | | |
| EVOLENT ONCOLOGY MEDICATION SCOPE | SPECIALTIES | COVERAGE | AUTHORIZATION |
| | <ul style="list-style-type: none"> • Gynecologic Oncology • Hematology • Medical Oncology • Neurological Oncology • Pediatric Oncology • Radiation Oncology • Surgical Oncology • Urology <p style="text-align: center;">(Medications only)</p> | <p>Place of Treatment:</p> <p>11-Provider office 19-Outpatient off-campus 22-Outpatient on-campus 24-Ambulatory</p> <p>Cancer Diagnosis = C00-D09, D37-D44, E34.0</p> <p>Hematology Diagnosis = D45-D49, D61.81, D61.2, D63.0, D63.8, D64.2- D64.3, D64.81, D64.89, D64.9, D68.59, D69.41, D69.59, D69.6, D69.8, D69.9, D70, D72.8, D72.9, D73.81, D73.9, D75.1, D75.81, D75.82</p> <p>N&V=R11</p> | <p>Authorization required for:</p> <p>All infused and oral* chemotherapy, hormonal therapeutic treatment, supportive agents, and symptom management medications.</p> <p><i>*Pharmacy benefit orals and office administered (medical benefit) infused/injectable agents of the same medication type (i.e., both cancer agents) must be submitted via one combined request.</i></p> |
| EVOLENT RADIATION ONCOLOGY SCOPE | SPECIALTIES | COVERAGE | AUTHORIZATION |

| | | | |
|---------------------------------|--|---|--|
| peach state health plan. | ambetter HEALTH | evolent | |
| AUTHORIZATION PROCESS | <ul style="list-style-type: none"> Radiation Oncology | <p>Place of Treatment:</p> <p>11-Provider office 19-Outpatient off-campus 22-Outpatient on-campus 24-Ambulatory</p> <p>Cancer Diagnosis = C00-D09, D37-D44, E34.0</p> <p>Hematology Diagnosis = D45-D49, D61.81, D61.2, D63.0, D63.8, D64.2-D64.3, D64.81, D64.89, D64.9, D68.59, D69.41, D69.59, D69.6, D69.8, D69.9, D70, D72.8, D72.9, D73.81, D73.9, D75.1, D75.81, D75.82</p> <p>N&V=R11</p> | <p>Authorization required for:</p> <ul style="list-style-type: none"> Brachytherapy Conformal 3D 2D, Electrons IMRT (Intensity-modulated radiation therapy) SBRT (Stereotactic body radiation therapy) IGRT (Image-guided radiation therapy) SRS (Stereotactic radiosurgery) Proton and neutron beam therapy |

Ordering provider's office must submit treatment requests to Evolent for prior authorization.

- Log on to the Evolent Carepro portal at <https://my.newcenturyhealth.com>
- Telephonic Intake: 888.999.7713
 - Medical Oncology - option 2
 - Radiation Oncology – option 3
- Physician Discussions: 888.999.7713
 - Medical Oncology - option 2, followed by option 5
 - Radiation Oncology – option 3, followed by option 5

HOURS OF OPERATION

Monday – Friday, 5:00 AM – 5:00 PM PST (fully staffed) *
 Saturday, 5:00 AM – 5:00 PM PST (limited staff) *
 Sunday, 5:00 AM – 2:00 PM PST (limited staff) *
 *After hours call coverage available:
 Monday – Saturday, 5:00 PM PST – 5:00 AM PST*
 Sunday, 2:00 PM PST – 5:00 AM PST*

| | | | | | |
|---------------------------------------|-------------------------|--|-------------------|---------------------------|-------------------|
| EVOLENT TURNAROUND TIMES (TAT) | Line of Business | Part B Medications | | Part D Medications | |
| | | Standard | Expedite | Standard | Expedite |
| | Exchange | 4 Calendar Days | 36 Calendar Hours | 36 Calendar Hours | 12 Calendar Hours |
| | Medicaid | 12 Hours | 12 Hours | 12 Hours | 12 Hours |
| | Line of Business | Radiation Oncology Medical Services | | | |
| | | Standard | | Expedite | |
| | Exchange | 4 Calendar Days | | 36 Calendar Hours | |

| | Medicaid | 2 Business Days | 12 Hours |
|-----------------------------------|--|-----------------|----------|
| MEDICATION CLINICAL TRIALS | <p>Clinical trials in scope for Evolent. Clinical trial drugs should be requested separately from standard of care medications generating 2 separate requests submitted to Evolent.</p> <ul style="list-style-type: none"> The clinical trial drug(s) should be submitted to Evolent – in the provider portal, step 5 of the request, indicate “Yes” this is a clinical trial, enter clinical trial name or number and proceed with your request. The standard of care medications should also be submitted to Evolent - in the provider portal, step 5 of the request, indicate ‘No’ to clinical trial and proceed with the request. <p>This process only applies if a member is <u>enrolled</u> in a clinical trial. If a member is only ‘following’ the clinical trial protocol, please submit one request for all drugs and indicate ‘No’ to clinical trial. Ensure supporting documentation clearly indicates member is either enrolled in clinical trial or only following protocol.</p> | | |
| TRANSPLANT SERVICES | <ul style="list-style-type: none"> Pre-Transplant: Send all chemotherapy regimen requests to Evolent for review. Post-Transplant: Transplant related chemotherapy authorizations requests within 1-year post-transplant should be sent to the health plan for review. | | |
| RETRO AUTHORIZATIONS | <p>Retrospective authorizations are out-of-scope for Evolent. Please appeal with Peach State Health Plan.</p> | | |
| EVOLENT PROVIDER SOLUTIONS | <p>Please contact your dedicated Provider Solutions Manager with any questions or to request Evolent in-service/training: Name: Betsy Roberts Email: Betsy.roberts@evolent.com Phone: 1.571.261.8621</p> | | |

| | |
|---|--|
| <p>EVOLENT RESOURCES</p> | <p>Resources available under “Useful Tool/Useful Documents” in Evolent’s Carepro portal:</p> <ul style="list-style-type: none"> • Clinical Data Elements: A resource tool to assist with answering the clinical questions presented during the prior authorization process. • Dose Optimization: As per the Hematology/Oncology Pharmacy Association (HOPA), rounding of biologic and cytotoxic agents within 10% of the standard dose is designated as acceptable for routine clinical care in both the curative and incurable settings; and changes less than or equal to 10% are not expected to reduce the safety or effectiveness of therapy. Evolent offers dose rounding for many chemotherapy drugs and encourages you to take advantage of the dose rounding opportunity by accepting the calculated dose. Neither accepting nor overriding the dose-rounded calculation has any impact on your authorization’s potential for auto-approval. • Evolent Level 1 Pathways: http://pathways.newcenturyhealth.com. Please share this link with your pharmacy and clinical team. • Oncology Supporting Documentation Grid (SDG) • Radiation Oncology Coding Guide: A resource tool to assist providers on how to submit radiation oncology treatment requests using appropriate CPT codes and quantities based on the number of treatments ordered. |
| <p>EVOLENT CLINICAL LEADERSHIP</p> | <p>Andrew Hertler, MD, FACP Chief Medical Officer Juhee Sidhu Vice President of Oncology Hugh Wallace, MD Sr. Medical Director Stanley Rubin, MD Sr. Medical Director Joel Schwartz, DO Radiation Oncology</p> |
| <p>EXCLUSIONS</p> | <ul style="list-style-type: none"> • Antibiotics • Bone marrow and stem cell transplants and CAR-T cell therapy • CKD/ESRD patients/medications • Controlled substances (i.e., Morphine) • Diagnostic imaging and diagnostic testing • Diagnostic radioisotopes • Equipment requests (infusion pumps) • Genetic lab testing and laboratory services • Hemophilia drugs • Home health • Inpatient radiation and chemotherapy treatments • Mozobil, Soliris and Ultomiris • Non-par providers • Radiation oncology clinical trials • Radiopharmaceuticals • Specialties, diagnoses, j-codes/CPT codes, places of treatment, and lines of business outside of defined scope • Surgeries/surgical procedures |